淋巴瘤患者的18F-FDG PET/MRI:究竟需要多少MRI信息
回顾性评估101例淋巴瘤患者的18F-FDG PET/MRI数据集,比较三种阅片方案(PET/MRI1仅T2加权HASTE加PET、PET/MRI2加增强VIBE、PET/MRI3加扩散加权成像)对病灶检测和分期的诊断效能。PET/MRI3在病灶检出和分期正确性上最高,基于PET/MRI1、PET/MRI2、PET/MRI3的治疗改变比例分别为11%、6%、3%。
要点
- PET/MRI3检出205/205个病灶、55/55例活动性淋巴瘤,分期正确96/101例。
- PET/MRI1检出190/205个病灶、53/55例活动性淋巴瘤,分期正确88/101例。
- 基于PET/MRI1、PET/MRI2、PET/MRI3的治疗改变比例分别为11%、6%、3%。
核心结论
- 在18F-FDG PET/MRI中附加增强和扩散加权成像可提高诊断能力,尤其对初始分期和正确分类疾病范围有潜在影响,可能影响患者和治疗管理。
研究设计与样本
- 共评估101例18F-FDG PET/MRI数据集,包括PET/MRI1(横断面T2加权HASTE加18F-FDG PET)、PET/MRI2(附加增强VIBE)和PET/MRI3(附加扩散加权成像)。
- 扫描用于初始分期、治疗中再分期、治疗结束时或怀疑肿瘤复发监测。
- 以既往PET/CT、所有可获得的随访和先前检查以及组织病理学作为参考标准。
主要发现
- PET/MRI1正确识别53/55例活动性淋巴瘤患者和190/205个病灶。
- PET/MRI2正确识别55/55例活动性淋巴瘤患者和202/205个病灶。
- PET/MRI3正确识别55/55例活动性淋巴瘤患者和205/205个病灶。
- PET/MRI1在101次检查中正确确定88次肿瘤分期,PET/MRI2为95/101,PET/MRI3为96/101。
- 基于PET/MRI1、PET/MRI2、PET/MRI3的治疗改变比例分别为11%、6%、3%。
关键数值与推荐
- 肿瘤分期参照修订的Ann Arbor分期系统标准确定。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate and compare the diagnostic potential of different reading protocols, entailing non-enhanced/contrast-enhanced and diffusion-weighted 18F-FDG PET/MR imaging for lesion detection and determination of the tumor stage in lymphoma patients. METHODS: A total of 101 18F-FDG PET/MRI datasets including a (1) transverse T2-w HASTE and 18F-FDG PET (PET/MRI1), (2) with an additional contrast enhanced VIBE (PET/MRI2), and (3) with additional diffusion-weighted imaging (PET/MRI3) were evaluated. Scans were performed for initial staging, restaging during treatment, or at the end of treatment and under surveillance with suspicion for tumor relapse. In all datasets lymphoma manifestations as well as tumor stage in analogy to the revised criteria of the Ann Arbor staging system were determined. Furthermore, potential changes in therapy compared to the reference standard were evaluated. Hitherto performed PET/CT and all available follow-up and prior examinations as well as histopathology served as reference standard. RESULTS: PET/MRI1 correctly identified 53/55 patients with active lymphoma and 190/205 lesions. Respective values were 55/55, 202/205 for PET/MRI2 and 55/55, 205/205 for PET/MRI3. PET/MRI1 determined correct tumor stage in 88 out of 101 examinations, and corresponding results for PET/MRI2 were 95 out of 101 and 96 out of 101 in PET/MRI3. Relating to the reference standard changes in treatment would occur in 11% based on PET/MRI1, in 6% based on PET/MRI2, and in 3% based on PET/MRI3. CONCLUSIONS: The additional application of contrast-enhanced and diffusion-weighted imaging to 18F-FDG PET/MRI resulted in higher diagnostic competence, particularly for initial staging and correct classification of the disease extent with potential impact on patient and therapy management.
引用
- Kirchner J, Deuschl C, Grueneisen J, et al. 18F-FDG PET/MRI in patients suffering from lymphoma: how much MRI information is really needed? Eur J Nucl Med Mol Imaging. 2017. PMID: 28161723. doi:10.1007/s00259-017-3635-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。